Description
Instil Bio is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer.
TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform.
ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.